Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Receivables (2016 - 2025)

Historic Receivables for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $13.4 million.

  • Cytosorbents' Receivables rose 1695.6% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year increase of 1695.6%. This contributed to the annual value of $11.7 million for FY2024, which is 1861.65% up from last year.
  • As of Q3 2025, Cytosorbents' Receivables stood at $13.4 million, which was up 1695.6% from $14.4 million recorded in Q2 2025.
  • Over the past 5 years, Cytosorbents' Receivables peaked at $14.4 million during Q2 2025, and registered a low of $7.5 million during Q4 2021.
  • Its 5-year average for Receivables is $10.6 million, with a median of $9.9 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Cytosorbents' Receivables was 5312.26% (2021), while the steepest drop was 774.67% (2021).
  • Cytosorbents' Receivables (Quarter) stood at $7.5 million in 2021, then rose by 26.09% to $9.5 million in 2022, then grew by 4.38% to $9.9 million in 2023, then increased by 18.62% to $11.7 million in 2024, then rose by 14.28% to $13.4 million in 2025.
  • Its Receivables was $13.4 million in Q3 2025, compared to $14.4 million in Q2 2025 and $13.5 million in Q1 2025.